Immunization in Alzheimer's disease: Naïve hope or realistic clinical potential?

Molecular Psychiatry

Volumn 14, Issue 3, 2009, Pages 239-251

  Foster, J K ^a,b,c,d   Verdile, G ^a,b,c   Bates, K A ^a,b,c   Martins, R N ^a,b,c  

^a HOLLYWOOD PRIVATE HOSPITAL   (Australia)

^b EDITH COWAN UNIVERSITY   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d Neurosciences Unit   (Australia)

Author keywords

amyloid; Brain; Cognition; Dementia; Immunotherapy

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN[1-42]; IMMUNOGLOBULIN; PLACEBO; POLYCLONAL ANTIBODY; QS 21;

ALZHEIMER DISEASE; ANTIBODY TITER; BRAIN ATROPHY; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; DRUG COST; DRUG SAFETY; FUNCTIONAL STATUS; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; MENINGOENCEPHALITIS; NERVE REGENERATION; NEUROTOXICITY; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; PROTEIN AGGREGATION; REVIEW;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; ANTIBODIES; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOTHERAPY, ACTIVE;

EID: 60549112186     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2008.115     Document Type: Review

References (67)

1. Lleo A, Greenberg SM, Growdon JH. Current pharmacotherapy for Alzheimer's disease. Annu Rev Med 2006; 57: 513-533.
2. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002; 297: 353-356.
3. Kemppainen NM, Aalto S, Wilson IA, Nagren K, Helin S, Bruck A et al. Voxel-based analysis of PET amyloid ligand [C-11]PIB uptake in Alzheimer disease. Neurology 2006; 67: 575-1580.
4. Shaw LM, Korecka M, Clark CM, Lee VMY, Trojanowski JQ. Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics. Nat Rev Drug Discov 2007; 6: 295-303.
5. Selkoe DJ. Toward a comprehensive theory for Alzheimer's disease - hypothesis: Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta-protein. Ann NY Acad Sci 2000; 924: 17-25.
6. Fiala M, Lin J, Ringman J, Kermani-Arab V, Tsao G, Patel A et al. Ineffective phagocytosis of amyloid-beta by macrophages of Alzheimer's disease patients. J Alzheimers Dis 2005; 7: 221-232.
7. Patterson C, Feightner J, Garcia A, MacKnight C. General risk factors for dementia: a systematic evidence review. Alzheimer Demen 2007; 3: 341-347.
8. Aksari P, Stoppe G. Risk factors of Alzheimer's disease - a review. Fortschr Neurol Psychiatr 1996; 64: 425-432.
9. Martins IJ, Hone E, Foster JK, Sunram-Lea SI, Gnjec A, Fuller SJ et al. Apolipoprotein E, cholesterol metabolism, diabetes, and the convergence of risk factors for Alzheimer's disease and cardiovascular disease. Mol Psychiatry 2006; 11: 721-736.
10. Stozicka Z, Zilka N, Novak M. Risk and protective factors for sporadic Alzheimer's disease. Acta Virol 2007; 51: 205-222.
11. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T et al. Immunization with amyloid-beta attenuates Alzheimer disease-like pathology in the PDAPP mouse. Nature 1999; 400: 173-177.
12. Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD et al. Abeta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 2000; 408: 979-982.
13. Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J et al. Abeta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2000; 408: 982-985.
14. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM. Peripheral anti-Abeta antibody alters CNS and plasma Abeta clearance and decreases brain Abeta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 2001; 98: 8850-8855.
15. McLaurin J, Cecal R, Kierstead ME, Tian X, Phinney AL, Manea M et al. Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis. Nat Med 2002; 8: 1263-1269.
16. Brendza RP, Bacskai BJ, Cirrito JR, Simmons KA, Skoch JM, Klunk WE et al. Anti-Abeta antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice. J Clin Invest 2005; 115: 428-433.
17. Becker M, Lavie V, Solomon B. Stimulation of endogenous neurogenesis by anti-EFRH immunization in transgenic mice model of Alzheimer's disease. Proc Natl Acad Sci USA 2007; 104: 1691-1696.
18. Foster JK. Hippocampus, recognition, and recall: a new twist on some old data? Behav Brain Sci 1999; 22: 449.
19. Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005; 64: 1553-1562.
20. Heppner FL, Gandy S, McLaurin J. Current concepts and future prospects for Alzheimer disease vaccines. Alzheimer Dis Assoc Disord 2004; 18: 38-43.
21. Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta 42 immunization. Neurology 2003; 61: 46-54.
22. Morris RG, Kopelman MD. The memory deficits in Alzheimer-type dementia - a review. Q J Exp Psychol A 1986; 38: 575-602.
23. Fox NC, Black RS, Gilman S, Rossor MN, Griffith SG, Jenkins L et al. Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology 2005; 64: 1563-1572.
24. Nicoll JAR, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 2003; 9: 448-452.
25. Ferrer I, Rovira MB, Guerra MLS, Rey MJ, Costa-Jussa F. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol 2004; 14: 11-20.
26. Masliah E, Hansen L, Adame A, Crews L, Bard F, Lee C et al. Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology 2005; 64: 129-131.
27. Fox N. Detecting change in Alzheimer's disease brains. Alzheimers Demen 2006; 2: S46.
28. Robinson SR, Bishop GA, Lee HG, Munch G. Lessons from the AN 1792 Alzheimer vaccine: lest we forget. Neurobiol Aging 2004; 25: 609-615.
29. Hock C, Konietzko U, Papassotiropoulos A, Wollmer A, Streffer J, von Rotz RC et al. Generation of antibodies specific for beta-amyloid by vaccination of patients with Alzheimer disease. Nat Med 2002; 8: 1270-1275.
30. Hock C, Konietzko U, Streffer JR, Tracy J, Signorell A, Muller-Tillmanns B et al. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron 2003; 38: 547-554.
31. Klatte ET, Scharre DW, Nagaraja HN, Davis RA, Beversdorf DQ. Combination therapy of donepezil and vitamin E in Alzheimer disease. Alzheimer Dis Assoc Disord 2003; 17: 113-116.
32. Winblad B, Engedal K, Soininen H, Verhey F, Waldemar G, Wimo A et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001; 57: 489-495.
33. Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A et al. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008; 372: 180-182.
34. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP et al. Copolymer-1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis - results of a phase-III multicenter, double-blind, placebo-controlled trial. Neurology 1995; 45: 1268-1276.
35. Frenkel D, Maron R, Burt DS, Weiner HL. Nasal vaccination with a proteosome-based adjuvant and glatiramer acetate clears beta-amyloid in a mouse model of Alzheimer disease. J Clin Invest 2005; 115: 2423-2433.
36. Agadjanyan MG, Ghochikyan A, Petrushina I, Vasilevko V, Movsesyan N, Mkrtichyan M et al. Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from beta-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide. J Immunol 2005; 174: 1580-1586.
37. Solomon B. Alzheimer's disease immunotherapy: from in vitro amyloid immunomodulation to in vivo vaccination. In: Perry G, Avila J, Kinoshita J, Smith MA (eds). Alzheimer's Disease: A Century of Scientific and Clinical Research. IOS Press: The Netherlands, 2006, pp 433-438.
38. Istrin G, Bosis E, Solomon B. Intravenous immunoglobulin enhances the clearance of fibrillar amyloid-beta peptide. J Neurosci Res 2006; 84: 434-443.
39. Ma QL, Lim GP, Harris-White ME, Yang F, Ambegaokar SS, Ubeda OJ et al. Antibodies against beta-amyloid reduce Abeta oligomers, glycogen synthase kinase-3beta activation and tau phosphorylation in vivo and in vitro. J Neurosci Res 2006; 83: 374-384.
40. Bacskai BJ, Kajdasz ST, Christie RH, Carter C, Games D, Seubert P et al. Imaging of amyloid-b deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat Med 2001; 7: 369-372.
41. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000; 6: 916-919.
42. Dodel RC, Du Y, Depboylu C, Hampel H, Frolich L, Haag A et al. Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. J Neurol Neurosurg Psychiatry 2004; 75: 1472-1474.
43. Relkin N, Szabo P, Adamiak B, Monthe C, Burgut FT, Du YS et al. Intravenous immunoglobulin (IVIg) treatment causes dose-dependent alterations in beta-amyloid (Abeta) levels and anti-beta antibody titres in plasma and cerebrospinal fluid (CSF) of Alzheimer's disease (AD) patients. Neurology 2005; 64(Suppl 1): A144-A145.
44. Poduslo JF, Curran GL. Amyloid beta peptide as a vaccine for Alzheimer's disease involves receptor-mediated transport at the blood-brain barrier. Neuroreport 2001; 12: 3197-3200.
45. Banks WA, Farr SA, Morley JE, Wolf KM, Geylis V, Steinitz M et al. Anti-amyloid beta protein antibody passage across the blood-brain barrier in the SAMP8 mouse model of Alzheimer's disease: an age-related selective uptake with reversal of learning impairment. Exp Neurol 2007; 206: 248-256.
46. Relkin NR, Younkin L, Younkin S, Monthe C, Adamiak B, Szabo P et al. Decreased plasma beta amyloid levels in Alzheimer patients treated chronically with Intravenous immunoglobulin (IVIg). Alzheimers Demen 2006; 2: S590.
47. Relkin NR. Intravenous immunoglobulin (IVIg) therapy. Alzheimers Demen 2006; 2: S51.
48. Szabo P, Esteban M, Monthé C, White L, Lent R, Relkin N et al. Increasing the efficacy of immunotherapy for Alzheimer's disease (AD) with intravenous immunoglobulin (IVIg). Alzheimers Demen 2006; 2: S361.
49. Adamiak B, Monthe C, Bender H, Szabo P, Schiff R, Weksler ME et al. Intravenous immunoglobulin (IVIg) maintains cognition over 18 months in patients with Alzheimer's disease (AD). Alzheimers Demen 2006; 2: S62-S63.
50. Pfeifer M, Boncristiano S, Bondolfi L, Stalder A, Deller T, Staufenbiel M et al. Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science 2002; 298: 1379.
51. Safavi A. Comparison of several human immunoglobulin products for anti-Abeta 1-42 titer. Alzheimers Demen 2006; 2: S591.
52. Mohajeri MH, Saini K, Schultz JG, Wollmer MA, Hock C, Nitsch RM. Passive immunization against beta-amyloid peptide protects central nervous system (CNS) neurons from increased vulnerability associated with an Alzheimer's disease-causing mutation. J Biol Chem 2002; 277: 33012-33017.
53. Morgan D. Modulation of microglial activation state following passive immunization in amyloid depositing transgenic mice. Neurochem Int 2006; 49: 190-194.
54. Geylis V, Kourilov V, Meiner Z, Nennesmo I, Bogdanovic N, Steinitz M. Human monoclonal antibodies against amyloid-beta from healthy adults. Neurobiol Aging 2005; 26: 597-606.
55. Tamura Y, Hamajima K, Matsui K, Yanoma S, Narita M, Tajima N et al. The F(ab')(2) fragment of an A beta-specific monoclonal antibody reduces A beta deposits in the brain. Neurobiol Dis 2005; 20: 541-549.
56. Lee EB, Leng LZ, Zhang B, Kwong L, Trojanowski JQ, Abel T et al. Targeting amyloid-beta peptide (Abeta) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Abeta precursor protein (APP) transgenic mice. J Biol Chem 2006; 281: 4292-4299.
57. Poduslo JF, Ramakrishnan M, Holasek SS, Ramirez-Alvarado M, Kandimalla KK, Gilles EJ et al. In vivo targeting of antibody fragments to the nervous system for Alzheimer's disease immunotherapy and molecular imaging of amyloid plaques. J Neurochem 2007; 102: 420-433.
58. Lambert MP, Velasco PT, Chang L, Viola KL, Fernandez S, Lacor PN et al. Monoclonal antibodies that target pathological assemblies of A-beta. J Neurochem 2007; 100: 23-35.
59. DeMattos RB, Racke MM, Bryan MT, Siemers ER. Passive immunotherapy with M266 results in altered CSF Ab. Alzheimers Demen 2006; 2: S589.
60. Morgan D. Immunotherapy for Alzheimer's disease. In: Perry G, Avila J, Kinoshita J, Smith MA (eds). Alzheimer's Disease: A Century of Scientific and Clinical Research. IOS Press: The Netherlands, 2006, pp 425-432.
61. Lee EB, Leng LZ, Lee VMY, Trojanowski JQ. Meningoencephalitis associated with passive immunization of a transgenic murine model of Alzheimer's amyloidosis. FEBS Letters 2005; 579: 2564-2568.
62. Agadjanyan M, Mamikonyan G, Necula M, Mkrtichyan M, Ghochikyan A, Petrushina I et al. Different susceptibilities of oligomeric and fibrillar forms of b-amyloid to antibodies specific to N-terminus of this peptide. Alzheimers Demen 2006; 2: S613-S614.
63. Merchiers P, van Dooren T, Van der Auwera I, Abulrob A, Lauwereys M, Roland B et al. Nanobodies targeting amyloid beta as potential therapeutics for Alzheimer's disease. Alzheimers Demen 2006; 2: S589.
64. Van Dooren T, Merchiers P, Borghgraef P, Dewachter I, Van der Auwera I, Wera S et al. Target specificity of nanobodies directed against amyloid peptides. Alzheimers Demen 2006; 2: S598-S599.
65. Bowers WJ, Mastrangelo MA, Stanley HA, Casey AE, Milo LJ, Federoff HJ. HSV amplicon-mediated Abeta vaccination in Tg2576 mice: differential antigen-specific immune responses. Neurobiol Aging 2005; 26: 393-407.
66. McGeer PL, McGeer E. Is there a future for vaccination as a treatment for Alzheimer's disease? Neurobiol Aging 2003; 24: 391-395.
67. Foster JK, Sohrabi H, Verdile G, Martins RN. Research criteria for the diagnosis of Alzheimer's disease: genetic risk factors, blood biomarkers and olfactory dysfunction. Int Psychogeriatr 2008; 20: 853-855.